U.S. Markets close in 5 hrs 34 mins

The Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price Has Soared 805%, Delighting Many Shareholders

Simply Wall St

For us, stock picking is in large part the hunt for the truly magnificent stocks. Not every pick can be a winner, but when you pick the right stock, you can win big. One bright shining star stock has been Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), which is 805% higher than three years ago. It's also good to see the share price up 87% over the last quarter.

It really delights us to see such great share price performance for investors.

See our latest analysis for Dicerna Pharmaceuticals

Given that Dicerna Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over the last three years Dicerna Pharmaceuticals has grown its revenue at 109% annually. That's much better than most loss-making companies. In light of this attractive revenue growth, it seems somewhat appropriate that the share price has been rocketing, boasting a gain of 108% per year, over the same period. Despite the strong run, top performers like Dicerna Pharmaceuticals have been known to go on winning for decades. So we'd recommend you take a closer look at this one, or even put it on your watchlist.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:DRNA Income Statement, December 15th 2019

If you are thinking of buying or selling Dicerna Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

We're pleased to report that Dicerna Pharmaceuticals shareholders have received a total shareholder return of 120% over one year. That gain is better than the annual TSR over five years, which is 9.8%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

Of course Dicerna Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.